Dendreon Corp (DNDN)

downwithpumpers (99.92) Submitted: 3/26/07 4:05 PM : Start Price: $4.90 DNDN Score: -28.11

After five straight successful calls it's time for for big one.

It has to be thumbs down based on the following reasons:
1. Slow/Poor trial enrollment
2. High executive turnover
3. No partners
4. Failed primary endpoints
5. Changing analysis (log-ra...

Report this Post Replies: 23 | Reply | Permalink

Providence (< 20) Submitted: 10/19/06 11:58 AM : Start Price: $5.13 DNDN Score: 19.67

Dendreon will get FDA approval next year. Their market for Provenge is 1-5 billion. With proof of concept, FDA approval and a cash infusion from a ROW partner, they should be able to accellerate the development of several new cancer vaccine therapies...

Report this Post Replies: 0 | Reply | Permalink

tomk0508 (95.28) Submitted: 2/03/08 11:19 PM : Start Price: $6.30 DNDN Score: 2.55

This company is sitting on a blockbuster advance in treatment of late stage prostrate cancer. The compound is a biologic and therefore is a bit of a political football with the FDA. Fortunately, the drug is relatively harmless and very effective fo...

Report this Post Replies: 0 | Reply | Permalink

eagleeyeinvestor (< 20) Submitted: 12/19/06 9:52 AM : Start Price: $4.18 DNDN Score: 45.53

The stock price is artificially being kept low by a hedge fund, and this offers great opportunity to accumulate the stock until FDA approval in the Spring. The drug will sell between $1B and $5 in its first 2 years and will be the best selling cance...

Report this Post Replies: 0 | Reply | Permalink

binarybit2 (< 20) Submitted: 12/09/06 11:15 AM : Start Price: $4.36 DNDN Score: 40.52

it has the proprietary Antigen Delivery Cassette™. This Antigen Delivery Cassette™ is then used to stimulate a patient’s immune system to recognize and destroy cells that express the target protein. This is a first of its kind cancer fighter.

Report this Post Replies: 0 | Reply | Permalink

techperson (< 20) Submitted: 5/02/07 2:51 PM : Start Price: $17.15 DNDN Score: -44.01

Dendreon has a date with the FDA on May 15 for final approval of Provenge. I think they'll get it, and there was a whopping 33.9 million short position as of the April 10 reporting date, or 41% of the outstanding shares. After getting killed by the...

Report this Post Replies: 0 | Reply | Permalink

EV38 (99.71) Submitted: 5/31/07 12:36 PM : Start Price: $9.63 DNDN Score: -18.42

ok...so this stock hit $25 on speculation that it might have been approved outright. When there was uncertainty again, it plunged to $5. Extrapolating the ranges vs the stock price, we're left with the assumption that the trials have a 25% as good a ...

Report this Post Replies: 0 | Reply | Permalink

LesMiles (76.74) Submitted: 5/30/06 10:05 PM : Start Price: $4.20 DNDN Score: 35.86

On fast track for FDA approval for Provenge its first therapeutic cancer vaccine (for prostate cancer). This drug has a very mild side effect profile while showing significant benefits.

Report this Post Replies: 0 | Reply | Permalink

McTwidget (< 20) Submitted: 4/05/07 1:24 PM : Start Price: $14.47 DNDN Score: -41.95

The pitches on DNDN show a lack of DD (especially the red thumbs). Yes, the runup was large...but the potential on this stock is much bigger than the price. The last remaining doubt will most likely be lifted by May 15th (FDA approval deadline - an...

Report this Post Replies: 0 | Reply | Permalink

Organik (< 20) Submitted: 12/25/06 4:33 PM : Start Price: $4.29 DNDN Score: 42.13

Phase 3 results demonstrate overall survival benefit for prostate cancer victims. FDA Priority Review likely to be granted by January '07. Approval may be given in May '07, if not before.

Report this Post Replies: 1 | Reply | Permalink